DexCom, Inc.
DXCM Healthcare Medical - Devices NASDAQ
$68.10
$-2.59 (-3.66%)
Open: $69.72 | High: $69.86 | Low: $67.64 | Prev Close: $70.69
Market Cap: $26.56B
Volume: 3.9M | Avg: 5.2M
Last updated: March 09, 2026 at 02:01 AMInvestment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 617
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 32.58 |
| P/B Ratio | 9.59 |
| P/S Ratio | 5.70 |
| EPS | $2.09 |
| Beta | 1.53 |
| Shares Outstanding | 390.02M |
| 52-Week High | $89.98 |
| 52-Week Low | $54.11 |
| SMA 50 | $70.61 |
| SMA 200 | $73.50 |
| Next Earnings | April 30, 2026 08:00 PM ET |
Financial Ratios
| Gross Margin | 60.1% |
| Operating Margin | 19.6% |
| Net Margin | 17.9% |
| ROE | 32.4% |
| ROA | 13.2% |
| Debt/Equity | 0.51 |
| Current Ratio | 1.88 |
| Quick Ratio | 1.59 |
Balance Sheet
| Total Assets | $6.34B |
| Total Liabilities | $3.59B |
| Total Equity | $2.75B |
|
|
|
| Cash | $917.70M |
| Total Debt | $1.39B |
| Net Debt | $472.00M |
Income Statement
| Revenue | $4.66B |
| Gross Profit | $2.80B |
| Operating Income | $911.80M |
| Net Income | $836.30M |
|
|
|
| EBITDA | $1.16B |
| Revenue/Share | $12.06 |
Cash Flow
| Operating CF | $1.44B |
| CapEx | $363.50M |
| Free Cash Flow | $1.08B |
|
|
|
| Book Value/Share | $7.10 |
| Tangible Book/Share | $6.86 |
| Equity/Share | $7.10 |
Technical Indicators
| RSI (14) | 42.77 Neutral |
| MACD |
0.26
Signal: 0.62
|
| Volatility | 29.59% |
| Trading Signal | Bearish |
Performance & Returns
| 1 Year | -21.69% |
| Sharpe Ratio | -0.68 Poor |
| Volatility (Ann.) | 39.42% Moderate |
| DXCM (1Y) | -21.69% |
| S&P 500 (1Y) | +13.03% |
| Alpha (Excess Return) | -34.72% |
Sector Comparison (Healthcare)
| Metric | DXCM | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 32.58 | 27.56 | 72% |
| P/B Ratio | 9.59 | -19.71 | 87% |
| ROE (%) | 32.44% | -9.91% | 81% |
| Net Margin (%) | 17.94% | 9.15% | 72% |
| Stock Score | 617 | 542.0 | 83% |
| 1Y Return (%) | -21.69 % | +8.73 % | 14% |
📊 Historical Price Analysis (Last 200 Days)
Loading chart...
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DXCM | $68.10 | $71.59 | $72.24 | $72.46 | $70.63 | $73.51 | 42.77 | 0.26 | 29.59% | 712994 | Strong Short | Bearish Stack |
Candlestick Patterns
There wasn't any recognizable pattern for the DXCM stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| DXCM | Why DexCom (DXCM) is a Top Momentum Stock for the Long-Term | Neutral | zacks.com | Read More |
| DXCM | Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026 | Neutral | businesswire.com | Read More |
| DXCM | 2 Growth Stocks to Hold for the Next Decade | Positive | fool.com | Read More |
| DXCM | Here's Why DexCom (DXCM) is a Strong Growth Stock | Positive | zacks.com | Read More |
| DXCM | DexCom, Inc. $DXCM Shares Sold by Alamar Capital Management LLC | Neutral | defenseworld.net | Read More |
Recent Insider Trading
| Date | Insider | Position | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-08 | SAYER KEVIN R | director, officer: Executive Chair | SELL | 32498 | $68.10 | $2213114 |
| 2026-03-08 | Sylvain Jereme M | officer: EVP, Chief Financal Officer | SELL | 18950 | $68.10 | $1290495 |
| 2026-03-08 | Brown Michael Jon | officer: EVP, Chief Legal Officer | SELL | 23325 | $68.10 | $1588433 |
| 2026-03-08 | Stern Sadie | officer: EVP, Chief HR Officer | SELL | 17199 | $68.10 | $1171252 |
| 2026-03-08 | Leach Jacob Steven | director, officer: President, CEO, and Director | SELL | 19757 | $68.10 | $1345452 |
Company Information
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
| CEO | Jacob Steven Leach |
| Employees | 10200 |
| Country | US |
| IPO Date | 2005-04-14 |
| Exchange | NASDAQ |
| Website | https://www.dexcom.com |
| Sector | Healthcare |
| Industry | Medical - Devices |
Similar Stocks (Healthcare - Medical - Devices)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category